Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;35(5):512-536.
doi: 10.1177/0269881120920420. Epub 2020 Sep 10.

Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy

Hans Emanuel Oeri  1
Affiliations
Review

Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy

Hans Emanuel Oeri. J Psychopharmacol. 2021 May.

Abstract

The last two decades have seen a revival of interest in the entactogen 3,4-methylenedioxy-N-methylamphetamine (MDMA) as an adjunct to psychotherapy, particularly for the treatment of post-traumatic stress disorder. While clinical results are highly promising, and MDMA is expected to be approved as a treatment in the near future, it is currently the only compound in its class of action that is being actively investigated as a medicine. This lack of alternatives to MDMA may prove detrimental to patients who do not respond well to the particular mechanism of action of MDMA or whose treatment calls for a modification of MDMA's effects. For instance, patients with existing cardiovascular conditions or with a prolonged history of stimulant drug use may not fit into the current model of MDMA-assisted psychotherapy, and could benefit from alternative drugs. This review examines the existing literature on a host of entactogenic drugs, which may prove to be useful alternatives in the future, paying particularly close attention to any neurotoxic risks, neuropharmacological mechanism of action and entactogenic commonalities with MDMA. The substances examined derive from the 1,3-benzodioxole, cathinone, benzofuran, aminoindane, indole and amphetamine classes. Several compounds from these classes are identified as potential alternatives to MDMA.

Keywords: Entactogen; MDMA; PTSD; empathogen; psychotherapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
(a) Phenethylamine, (b) MDMA, (c) MDA, (d) MBDB, (e) BDB, (f) MDEA. BDB: 1-(1,3-benzodioxol-5-yl)-2-butanamine; MBDB: 1-(1,3-benzodioxol-5-yl)-N-methyl-2-butanamine; MDA: 3,4-methylenedioxyamphetamine; MDEA: 3,4-methylenedioxy-N-ethyl-amphetamine; MDMA: 3,4-methylenedioxy-N-methylamphetamine.
Figure 2.
Figure 2.
(a) Dextroamphetamine, (b) cathinone, (c) MDCATH, (d) methylone, (e) ethylone, (f), butylone, (g) mephedrone, (h) MDPV, (i) MDCATH dimer. MDCATH: 2-amino-(3,4-methylenedioxy)propiophenone; MDPV: methylenedioxypyrovalerone.
Figure 3.
Figure 3.
(a) 5-APB, (b) 5-MAPB, (c) 6-APB, (d) 6-MAPB, (e) 6-APDB. 6-APB: 6-(2-aminopropyl)-benzofuran; 5-APB: 5-(2-aminopropyl)-benzofuran; 6-APDB: 2,3-dihydro isomer of 6-APB 5-MAPB; 6-MAPB: 5-(2-methylaminopropyl) benzofuran.
Figure 4.
Figure 4.
(a) 2-AI, (b) MDAI, (c) 5-IAI, (d) MMAI. 2-AI: 2-aminoindane; 5-IAI: 5-iodo-2-aminoindane; MDAI: 5,6-methylenedioxy-2-aminoindane; MMAI: 5-methoxy-6-methyl-2-aminoindane.
Figure 5.
Figure 5.
(a) α-ET, (b) 4-FA. α-ET: α-ethyltryptamine; 4-FA: 4-fluoroamphetamine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aarde SM, Huang PK, Creehan KM, et al.. (2013) The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: Self-administration and locomotor activity in rats. Neuropharmacology 71: 130–140. - PMC - PubMed
    1. Anneken JH, Angoa-Pérez M, Kuhn DM. (2015) 3,4-methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter. J Neurochem 133: 211–222. - PMC - PubMed
    1. Ask AL, Fagervall I, Huang RB, et al.. (1989) Release of 3H-5-hydroxytryptamine by amiflamine and related phenylalkylamines from rat occipital cortex slices. Naunyn Schmiedebergs Arch Pharmacol 339: 684–689. - PubMed
    1. Baggott MJ, Coyle JR, Siegrist JD, et al.. (2016) Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol 30: 378–387. - PubMed
    1. Baggott MJ, Garrison KJ, Coyle JR, et al., (2019) Effects of the psychedelic amphetamine MDA (3,4-methylenedioxyamphetamine) in healthy volunteers. J Psychoactive Drugs 51: 108–117. - PubMed

MeSH terms

Substances